scPharmaceuticals (SCPH) AI Stock Analysis

Compare

489 Followers

SCPH Dividends

Top Page

scPharmaceuticals

(NASDAQ:SCPH)

43Neutral

scPharmaceuticals demonstrates strong revenue growth potential and strategic advancements such as FDA approval for expanded use. However, significant financial challenges persist, including high debt, negative equity, and increased operating expenses. Technical indicators also highlight a bearish trend. These factors result in a cautious overall stock score.

Positive Factors

FDA Approval

FDA approval of the sNDA for Furoscix meaningfully expands its labeled indication to include edema in patients with chronic kidney disease (CKD), representing a significant positive milestone.

Market Expansion

The expansion to CKD is a significant market opportunity and expands Furoscix’s prescriber base to nephrologists.

Sales Growth

Furoscix Integrated Delivery Networks/hospital systems sales in 4Q24 increased 123% quarter-over-quarter and were approximately 10% of total sales.

Negative Factors

Cost Concerns

The autoinjector submission remains on track and may reduce costs associated with Furoscix by approximately 70%.

Sales Forecast

The long-term peak sales forecast for Furoscix in heart failure and chronic kidney disease has been lowered to reflect a more measured uptake trajectory.

scPharmaceuticals (SCPH) vs. S&P 500 (SPY)

Market Cap

$115.15M

Dividend YieldN/A

Average Volume (3M)397.79K

Price to Earnings (P/E)―

Beta (1Y)1.01

Revenue Growth167.28%

EPS Growth-34.13%

CountryUS

Employees162

SectorHealthcare

Sector Strength54

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.35

Shares Outstanding50,283,924

10 Day Avg. Volume189,733

30 Day Avg. Volume397,787

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

Price to Cash Flow (P/CF)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.44

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit6.66

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$16.50

Price Target Upside557.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

scPharmaceuticals Business Overview & Revenue Model

Company DescriptionscPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

How the Company Makes MoneyscPharmaceuticals generates revenue primarily through the commercialization of its lead product, FUROSCIX. The company makes money by selling this product directly to healthcare providers, pharmacies, and through partnerships with specialty pharmacies that distribute to patients. Revenue streams are bolstered by pricing agreements and contracts with healthcare systems and insurance companies, which reimburse the use of their products. The company's earnings are also supported by ongoing research and development efforts to expand their product pipeline and enhance existing offerings.

scPharmaceuticals Financial Statement Overview

Summary

scPharmaceuticals shows promising revenue growth, yet faces significant challenges in profitability, leverage, and cash flow. The company's high debt levels and negative equity position indicate financial instability, while negative cash flows suggest ongoing operational difficulties. Continued focus on improving operational efficiency and financial health is essential for future stability and growth.

Income Statement

―

The company demonstrated a significant increase in revenue from 2023 to 2024, showing positive growth potential. However, profitability remains a concern, with consistent net losses and negative EBIT and EBITDA margins, indicating challenges in achieving operational efficiency and profitability.

Balance Sheet

The balance sheet reflects a high debt-to-equity ratio, indicating significant leverage and potential financial risk. Negative stockholders' equity is a concern, suggesting liabilities exceed assets, which may pose financial stability risks. The equity ratio is negative, highlighting the company's reliance on debt financing.

Cash Flow

―

Operating cash flow remains negative, reflecting ongoing operational challenges. Free cash flow is also negative, indicating cash outflows exceed cash inflows, which may impact the company's ability to fund operations and growth without external financing.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
36.33M	13.59M	0.00	0.00	0.00
	Gross Profit
24.97M	9.78M	-468.00K	-438.00K	-399.00K
	EBIT
-64.78M	-55.40M	-36.16M	-25.82M	-29.93M
	EBITDA
-77.56M	-46.06M	-33.07M	-25.02M	-29.22M
	Net Income Common Stockholders
-85.15M	-54.81M	-37.52M	-30.49M	-34.39M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
75.66M	76.01M	118.37M	75.46M	105.28M
	Total Assets
107.52M	94.48M	124.19M	79.04M	109.05M
	Total Debt
52.69M	40.27M	37.37M	17.64M	20.21M
	Net Debt
-22.96M	-6.54M	-33.69M	-56.63M	-85.07M
	Total Liabilities
94.20M	57.26M	51.76M	22.57M	26.88M
	Stockholders Equity
13.32M	37.22M	-226.54M	-189.70M	-161.66M
Cash Flow		Free Cash Flow
-70.56M	-59.28M	-34.60M	-27.16M	-27.69M
	Operating Cash Flow
-70.54M	-59.24M	-34.58M	-27.15M	-27.69M
	Investing Cash Flow
29.30M	19.96M	-45.86M	32.13M	-33.46M
	Financing Cash Flow
70.08M	14.85M	77.23M	-2.53M	60.35M

scPharmaceuticals Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price2.51

Price Trends

50DMA

2.71

Negative

100DMA

3.05

Negative

200DMA

3.74

Negative

Market Momentum

MACD

-0.06

Negative

RSI

48.69

Neutral

STOCH

40.83

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCPH, the sentiment is Neutral. The current price of 2.51 is above the 20-day moving average (MA) of 2.48, below the 50-day MA of 2.71, and below the 200-day MA of 3.74, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 48.69 is Neutral, neither overbought nor oversold. The STOCH value of 40.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SCPH.

scPharmaceuticals Risk Analysis

scPharmaceuticals disclosed 70 risk factors in its most recent earnings report. scPharmaceuticals reported the most risks in the “Tech & Innovation” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

scPharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (52)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.21B	3.55	-41.91%	2.83%	15.12%	0.42%
RGLS	52 Neutral	$518.69M	―	-95.00%	―	―	44.85%
TNXP	50 Neutral	$130.27M	―	-106.12%	―	29.94%	-241.81%
LRMR	49 Neutral	$134.46M	―	-50.77%	―	―	-54.29%
NKTR	48 Neutral	$119.48M	―	-124.10%	―	9.22%	60.01%
SCPH	43 Neutral	$115.15M	―	-336.97%	―	167.28%	-34.13%
KOD	35 Underperform	$200.50M	―	-84.70%	―	―	32.58%

* Healthcare Sector Average

Performance Comparison

SCPH

scPharmaceuticals

2.51

-1.97

-43.97%

NKTR

Nektar Therapeutics

0.59

-1.17

-66.48%

RGLS

Regulus

7.85

5.64

255.20%

TNXP

Tonix Pharma

18.83

-530.61

-96.57%

LRMR

Larimar Therapeutics

2.24

-4.88

-68.54%

KOD

Kodiak Sciences

4.00

0.39

10.80%

scPharmaceuticals Earnings Call Summary

Earnings Call Date:Mar 19, 2025

(Q4-2024)

% Change Since: -17.43%|

Next Earnings Date:May 14, 2025

Earnings Call Sentiment Positive

The earnings call reflected a positive sentiment overall, with strong revenue growth and strategic advancements like the FDA approval for CKD. However, increased operating expenses and a higher net loss pose challenges. The company is optimistic about future growth driven by Medicare redesign and product expansion.

Q4-2024 Updates

Positive Updates

Significant Revenue Growth

scPharmaceuticals reported $36.3 million in FUROSCIX net revenue for 2024, marking a 167% increase year-over-year.

FDA Approval for Expanded Use

The FDA approved FUROSCIX for the treatment of edema in patients with chronic kidney disease, expanding its market potential.

Increased Provider Adoption

Over 3,800 unique providers have prescribed FUROSCIX, with doses filled increasing by 23% in Q4 compared to Q3.

Positive Patient Co-pay Developments

The Medicare redesign is expected to lower patient out-of-pocket costs significantly, potentially increasing fill rates and demand.

Autoinjector Progress

Encouraging data from shelf-life testing of the Autoinjector, with a mid-year submission of the sNDA planned.

Negative Updates

Increased Operating Expenses

Selling, general, and administrative expenses rose to $77.6 million for 2024, a significant increase from $53.4 million in 2023.

Higher Net Loss

The company's net loss for 2024 was $85.1 million, up from $54.8 million in 2023.

Continued Gross to Net Discount Challenges

The gross to net discount for FUROSCIX was approximately 19% in Q4, expected to increase to 30-35% in 2025 due to Medicare redesign.

Company Guidance

During the scPharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call, the company reported a net revenue of $12.2 million for Q4 2024, leading to a total of $36.3 million in net FUROSCIX revenue for the year, marking a 167% increase year-over-year. The company highlighted a gross-to-net (GTN) discount of approximately 19% for Q4 2024 and projected a long-term GTN discount range of 30% to 35% for 2025 due to the Medicare redesign. scPharmaceuticals announced the FDA's approval of a supplemental new drug application for FUROSCIX to treat edema in chronic kidney disease (CKD) patients, with a full launch expected in April 2025. The company also noted a significant increase in the number of doses prescribed, citing 13,300 doses filled in Q4 2024, up from 10,800 in Q3 2024. Additionally, the company ended 2024 with $75.7 million in cash and reported a Q4 net loss of $18.8 million. Looking ahead, scPharmaceuticals anticipates the Medicare redesign to positively impact FUROSCIX's market penetration and organic growth.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.